Voyageur Pharmaceuticals Ltd. has announced independent laboratory test results confirming its natural barium sulfate active pharmaceutical ingredient meets pharmaceutical-grade standards, with purity levels exceeding 98.8% BaSO4 and full United States Pharmacopeia compliance. The testing, conducted by SGS Laboratories in Mississauga, Ontario, revealed assay results ranging from 98.1% to 99.4% across multiple samples, surpassing the USP monograph requirement of 97.5%. These results represent a significant milestone for the company's development of contrast media for medical imaging applications.
The processed barite from Voyageur's Frances Creek property in British Columbia underwent comprehensive testing that included identification, pH, loss on drying, limit of soluble barium salts, acid-soluble substances, sulfides, and microbiological requirements. USP elemental impurities testing showed heavy metal levels significantly lower than specifications. The material achieved 1-micron and 10-micron particle sizes through processing at Sturtevant Inc. using pharmaceutical-grade micronizing equipment, with d50 values of 1.1-1.9 µm and d90 values as low as 2.5 µm under optimal conditions. All micronized samples met USP particle size and performance criteria while exhibiting good flowability and 100% yield.
With these results, Voyageur anticipates advancing to stage two of the Alberta Innovates AICE-Market Access Program, which includes manufacturing barium contrast agents for an upcoming clinical trial designed by Chief Scientific Officer Dr. Iryna Saranchova in accordance with Health Canada standards. The clinical trial will compare Voyageur's contrasts with current commercially available standard-of-care options for gastrointestinal Computed Tomography and fluoroscopic imaging applications. By evaluating investigational agents against both barium-based and iodinated oral contrasts, the trial is expected to provide comprehensive assessment of product performance in clinical settings.
Successful study outcomes could validate clinical performance of Voyageur's developing imaging contrasts, strengthen regulatory positioning, and accelerate progress toward market adoption. The clinical trial results will be pivotal for marketing and enhancing the company's FDA licensing applications, with the FDA process beginning in the first quarter of 2026. Full study completion is targeted for the fourth quarter of 2026. These developments also contribute to the prefeasibility and final feasibility study for the Frances Creek project, expected by the fourth quarter of 2026.
Brent Willis, CEO of Voyageur, stated that these results represent a major de-risking milestone and bring the company significantly closer to a fully integrated, secure, and cost-effective North American supply chain for barium contrast media. The company believes it has proven that its natural barite resource delivers high chemical purity, ideal particle size after micronization, and full USP compliance. The upcoming clinical trial in patients represents the final bridge to using Frances Creek API in Health Canada-approved contrast products.
By developing this domestic resource, Voyageur is building a fully integrated supply chain from quarry to finished contrast media, reducing reliance on imported or synthetic materials while improving cost efficiency and supply reliability for hospitals and patients. The world's pharmaceutical barium sulfate is currently almost entirely synthetically produced, which management believes results in less effective imaging quality. Voyageur's Frances Creek resource boasts a rare and high-grade mineral suitable for the pharmaceutical marketplace that could potentially replace current synthetic products with higher quality, lower cost imaging products.
